These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8359564)

  • 21. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Dai Q
    J Clin Endocrinol Metab; 1993 Jan; 76(1):32-7. PubMed ID: 8421099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sandostatin LAR in acromegalic patients: a dose-range study.
    Fløgstad AK; Halse J; Haldorsen T; Lancranjan I; Marbach P; Bruns C; Jervell J
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3601-7. PubMed ID: 8530606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Octreotide treatment of acromegaly.
    Wass JA
    Horm Res; 1990; 33 Suppl 1():1-5; discussion 6. PubMed ID: 2358294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
    Mercado M; Borges F; Bouterfa H; Chang TC; Chervin A; Farrall AJ; Patocs A; Petersenn S; Podoba J; Safari M; Wardlaw J;
    Clin Endocrinol (Oxf); 2007 Jun; 66(6):859-68. PubMed ID: 17465997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R
    Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly.
    Stewart PM; Kane KF; Stewart SE; Lancranjan I; Sheppard MC
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3267-72. PubMed ID: 7593436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatostatin analogs in the treatment of acromegaly.
    Lamberts SW; Reubi JC; Krenning EP
    Endocrinol Metab Clin North Am; 1992 Sep; 21(3):737-52. PubMed ID: 1355729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Octreotide.
    Lamberts SW; van der Lely AJ; de Herder WW; Hofland LJ
    N Engl J Med; 1996 Jan; 334(4):246-54. PubMed ID: 8532003
    [No Abstract]   [Full Text] [Related]  

  • 29. The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.
    Tauber JP; Poncet MF; Harris AG; Barthel HR; Simonetta-Chateauneuf C; Buscail L; Bayard F
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3262-6. PubMed ID: 7593435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term treatment of acromegaly with octreotide (Sandostatin).
    Page MD; Millward ME; Hourihan M; Hall R; Scanlon NF
    Horm Res; 1990; 33 Suppl 1():20-30; discussion 30-1. PubMed ID: 2192978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of therapy-resistant acromegaly using Sandostatin].
    von Werder K; Mehltretter G; Müller OA
    Z Gastroenterol; 1990 Sep; 28 Suppl 2():29-31. PubMed ID: 1980775
    [No Abstract]   [Full Text] [Related]  

  • 32. Hair loss in three patients with acromegaly treated with octreotide.
    Lami MC; Hadjadj S; Guillet G
    Br J Dermatol; 2003 Sep; 149(3):655-6. PubMed ID: 14511007
    [No Abstract]   [Full Text] [Related]  

  • 33. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group.
    Sassolas G; Harris AG; James-Deidier A
    J Clin Endocrinol Metab; 1990 Aug; 71(2):391-7. PubMed ID: 2199479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prospective study of functional changes in the gallbladder and formation of gallstones induced by long-term treatment of somatostatin analogue SMS201-995 in patients of active acromegaly].
    Zhu XF; Shi YF; Zhang JX
    Zhonghua Nei Ke Za Zhi; 1991 Jul; 30(7):405-8, 455. PubMed ID: 1752152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective treatment of recurrent acromegaly with a long-active somatostatin analogue (sandostatin).
    Miranda R; Zárate A; Ruíz Velasco G
    Arch Invest Med (Mex); 1988; 19(4):445-8. PubMed ID: 3245759
    [No Abstract]   [Full Text] [Related]  

  • 36. Sandostatin (octreotide acetate).
    Claussen D
    Gastroenterol Nurs; 1992 Dec; 15(3):122-4. PubMed ID: 1472557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
    Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Long acting sandostatine (sandostatine LAR) in the treatment of acromegaly].
    Priou A; Levesque G; Simonetta C; Lancranjan I; Roger P; Jaquet P
    Ann Endocrinol (Paris); 1995; 56(3):213-8. PubMed ID: 7677407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Octreotide, analog of somatostatin. Pharmacological properties and therapeutic applications in pituitary endocrine tumors].
    Chanson P; Timsit J; Harris AG
    Presse Med; 1993 Dec; 22(40):2009-16. PubMed ID: 7907419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.